Crizotinib

ArtNr	HY-50878-5mg
Hersteller	MedChem Express
CAS-Nr.	877399-52-5
Menge	5 mg
Quantity options	100 mg 10mM/1mL 10 mg 200 mg 500 mg 50 mg 5 mg
Kategorie	Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Specific against	other
Purity	99.97
Formula	C21H22Cl2FN5O
Citations	ACS Omega. 2023 Jun 14. Arch Biochem Biophys. 2024 Jan 26:109905. Biochem Pharmacol. 2021 Aug;190:114620. Biochim Biophys Acta Mol Cell Res. 2020 Jul;1867(7):118712. Biol Methods Protoc. 2025 Feb 13. Biomark Res. 2024 Jan 25;12(1):13. Biomed Chromatogr. 2019 Oct;33(10):e4611. Biomed Chromatogr. 2024 Oct;38(10):e5986. bioRxiv. 2024 Nov 6:2024.11.04.621884. Blood Adv. 2023 Feb 10;bloodadvances.2022008384. Blood. 2021 Oct 17;blood.2020008136. Braz J Pharm Sci. 2015 Jun;51(2):2175-9790. Cancer Discov. 2018 Mar;8(3):354-369. Cancer Discov. 2023 Mar 1;13(3):598-615. Cancer Discov. 2024 Sep 13:OF1-OF20. Cancer Lett. 2018 May 28;422:19-28. Cancer Med. 2020 Jun;9(12):4350-4359. Cancer Res. 2015 Nov 1;75(21):4548-59. Cancers (Basel). 2017 Oct 30;9(11). pii: E149. Cancers (Basel). 2024 Cell Rep Med. 2023 Jan 10;100911. Cell Rep Med. 2024 Mar 19;5(3):101472. Cell Rep Methods. 2023 Oct 23;3(10):100599. Dis Model Mech. 2016 Sep 1;9(9):941-52. Eberhard Karls Universität Tübingen. 2023 Sep 18. EBioMedicine. 2022 Dec 14;87:104410. Eur J Drug Metab Pharmacokinet. 2021 Jul 18;1-11. Eur J Med Chem. 2017 Oct 20;139:674-697. Evid Based Complement Alternat Med. 2019 Nov 7;2019:4253846. Exp Cell Res. 2020 Aug 1;393(1):112054. Front Oncol. 2020 May 12;10:696. Fundam Clin Pharmacol. 2021 Feb 1. Harvard Medical School LINCS LIBRARY Int J Mol Sci. 2022 Sep 17;23(18):10895. Invest New Drugs. 2023 Apr 10. J Cancer Res Clin Oncol. 2021 Jan;147(1):167-175. J Exp Clin Cancer Res. 2022 Mar 29;41(1):113. J Med Chem. 2021 Mar 11;64(5):2725-2738. J Med Chem. 2021 Sep 21. J Med Chem. 2024 Oct 3. J Pharm Anal. 2021 Jun 19. J Solution Chem. 2014 Jul;43(7):1282-1295. J Transl Med. 2023 Aug 5;21(1):530. Mol Oncol. 2017 Aug;11(8):996-1006. Nat Biomed Eng. 2018 Aug;2(8):578-588. Oncogene. 2018 Mar;37(11):1417-1429. Oncogene. 2024 Aug 29. Oncotarget. 2014 May 15;5(9):2688-702. Oncotarget. 2016 May 17;7(20):29011-22. Oncotarget. 2019 Aug 13;10(48):4937-4950. PLoS One. 2021 Jun 8;16(6):e0252907. PLoS One. 2025 Jan 21;20(1):e0308747. PLoS One. 2019 Feb 11;14(2):e0212048. Proteomes. 2023 Jun 2, 11(2), 20. Research Square Preprint. 2022 Feb. Research Square Print. 26 Oct, 2022 Research Square Print. September 14th, 2022. Saudi Pharm J. 2015 Jan;23(1):75-84. Sci Signal. 2014 Oct 28;7(349):ra102. Sci Signal. 2015 Dec 8;8(406):ra125. Sci Transl Med. 1 Sep 2021. Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. Signal Transduct Target Ther. 2024 Mar 9;9(1):65. Spectrochim Acta A Mol Biomol Spectrosc. 2014 Oct 15;131:347-54. Spectrochim Acta A Mol Biomol Spectrosc. 2021 Oct 5;259:119884. Stem Cell Reports. 2017 Dec 12;9(6):1948-1960. Talanta. 2019 Aug 15;201:217-225. Technical University of Munich. 24.01.2018. Transl Oncol. 2021 Jan;14(1):100887. Transl Oncol. 2021 Nov 22;15(1):101272. Int J Antimicrob Agents. 2025 Mar 4:107470. J Hematol Oncol. 2018 Aug 29;11(1):109. [1]Zou HY, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007, 67(9), 4408-4417. [2]Christensen JG, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007, 6(12 Pt 1), 3314-3322. [3]Cui JJ, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011 Sep 22;54(18):6342-63. [4]Cullinane C, et al. Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models. J Nucl Med. 2011 Aug;52(8):1261-7 [5]Shen A, et al. c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers. Cancer Res. 2015 Nov 1;75(21):4548-59. [6]Umapathy G, et al. The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma. Sci Signal. 2014 Oct 28;7(349):ra102. [7]Tucker ER, et al. Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma. Mol Oncol. 2017 Aug;11(8):996-1006. [8]Liu H, et al. Identifying and Targeting Sporadic Oncogenic GeneticLiu H, et al. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer. Cancer Discov. 2018 Mar;8(3):354-369.
Smiles	ClC1=C(F)C=CC(Cl)=C1[C@H](OC2=CC(C3=CN(N=C3)C4CCNCC4)=CN=C2N)C
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	PF-02341066
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Anaplastic lymphoma kinase (ALK); Autophagy; c-Met/HGFR; ROS Kinase
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	450.34
Product Description	Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition[1][2][3].
Manufacturer - Research Area	Cancer
Solubility	DMSO : 20 mg/mL (ultrasonic; warming; heat to 60°C)\|H2O : < 0.1 mg/mL (ultrasonic)
Manufacturer - Pathway	Autophagy; Protein Tyrosine Kinase/RTK
Clinical information	Launched

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-50878-5mg-safety-datasheet.pdf